ReviewJournal of eating disorders2026
A scoping review on weight loss injections and eating disorders: therapeutic impact, risks of misuse, and emerging harms.
Review in Journal of eating disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimGLP-1 receptor and GIP agonists are widely used for weight loss in obesity, with strong evidence supporting their efficacy, and their potential positive impact on binge eating disorders. However, little is known about their use in individuals with eating disorders. Despite growing concerns, research exploring this intersection is limited, and clinical guidance is lacking.
objectivesThis scoping review explores existing literature on weight loss injections in the context of eating disorder development and treatment to identify gaps and inform future practice.
methodsThe scoping review searched six electronic databases (Embase, MEDLINE, PsycINFO, AMED, HMIC, and Emcare) in April 2025. Studies were eligible if they focused on the use of weight loss injections (GLP-1 receptor agonists), in individuals with current or past eating disorders, including all diagnoses. Both clinical and non-clinical settings were included, with no age or geographical restrictions.
resultsA total of 80 records were identified through database searches. After title and abstract screening, 11 full-text articles were assessed for eligibility. Two papers were excluded due to the absence of empirical data, resulting in 9 studies being included in the final review.
conclusionsOverall, there is very limited evidence exploring the psychological impact of GLP-1 receptor agonists on individuals with eating disorders. While some findings suggest potential benefits for managing binge eating symptoms in populations with comorbid type 2 diabetes, there is a significant gap in our understanding of how these medications may influence disordered eating behaviours and body image concerns, particularly when used outside of weight-based indicators. Further research is essential to inform clinical guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.